文献速递咽喉与嗓音

声带瘢痕单次诊室激素注射后的嗓音结局

Voice Outcomes following a Single Office-Based Steroid Injection for Vocal Fold Scar.
PubMed 文献 · Otolaryngol Head Neck Surg · 2016-08-09

本研究为病例系列加病历回顾,纳入25例轻至中度声带瘢痕患者,接受诊室地塞米松注射至浅层固有层。注射后嗓音障碍指数(n=24,P<.001)、声门功能指数(n=22,P<.001)、GRBAS总分(n=25,P<.001)、基频范围(n=24,P=.024)、发声阈值压力(n=14,P=.017)及部分视频频闪喉镜参数均改善。作者认为该治疗联合嗓音治疗与嗓音结局改善相关,并提供初步支持。

要点

  • 诊室地塞米松注射至浅层固有层后,嗓音障碍指数与声门功能指数下降(P<.001)。
  • GRBAS总分下降(n=25,P<.001),基频范围增加(n=24,P=.024)。
  • 发声阈值压力下降(n=14,P=.017),声带边缘、声门闭合及右侧黏膜波改善。

核心结论

  • 诊室激素注射联合嗓音治疗用于轻至中度声带瘢痕,与患者报告及功能嗓音指标改善相关;这些发现为该疗法提供初步支持。
  • 作者认为该操作风险低且可在诊室完成,为传统上难以管理的患者提供一种简单的治疗选择;有必要开展前瞻性研究评估多次注射的效果。

研究设计与样本

  • 研究设计为病例系列加病历回顾,地点为学术医疗中心。
  • 样本为25例接受诊室地塞米松注射至浅层固有层治疗的轻至中度声带瘢痕患者。
  • 研究基于患者报告、感知、声学、空气动力学及视频频闪喉镜参数的术前与术后分析。
  • 平均随访13.7±4.4周;患者在评估之间完成3.5±2.3次嗓音治疗。
  • 各参数并非均有完整数据集;样本量在结果中注明。

主要发现

  • 嗓音障碍指数下降(n=24;P<.001),声门功能指数下降(n=22;P<.001)。
  • GRBAS总分(分级、粗糙度、气息声、无力感、紧张感)下降(n=25;P<.001)。
  • 基频范围增加(n=24;P=.024)。
  • 发声阈值压力下降(n=14;P=.017)。
  • 视频频闪喉镜参数中声带边缘(P=.004)、声门闭合(P=.003)及右侧黏膜波(P=.016)在注射后改善。

临床怎么用

  • 作者认为诊室激素注射联合嗓音治疗用于轻至中度声带瘢痕与患者报告及功能嗓音指标改善相关,这些发现提供初步支持。
  • 作者认为该操作风险低且可在诊室完成,为传统上难以管理的患者提供一种简单的治疗选择。
  • 作者提出有必要开展前瞻性研究评估多次注射的效果。

局限性

  • 各参数并非均有完整数据集;样本量在结果中注明。
  • 作者提出有必要开展前瞻性研究评估多次注射的效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Persistent dysphonia from vocal fold scar remains a clinical challenge, with current therapies providing inconsistent outcomes. We evaluated voice outcomes after a single office-based steroid injection. STUDY DESIGN: Case series with chart review. SETTING: Academic medical center. SUBJECTS AND METHODS: This study was based on pre- and postoperative analysis of patient-reported, perceptual, acoustic, aerodynamic, and videostroboscopic parameters. The sample comprised 25 patients undergoing office-based dexamethasone injection into the superficial lamina propria for mild/moderate vocal fold scar. Average follow-up was 13.7 ± 4.4 weeks; patients completed 3.5 ± 2.3 sessions of voice therapy between assessments. Complete data sets were not available for each parameter; sample size is noted with results. RESULTS: Voice handicap index (n = 24; P < .001) and glottal function index (n = 22; P < .001) decreased after injection. Total GRBAS score (grade, roughness, breathiness, asthenia, strain) decreased (n = 25; P < .001). Fundamental frequency range increased (n = 24; P = .024). Phonation threshold pressure decreased (n = 14; P = .017). Videostroboscopic parameters of vocal fold edge (P = .004), glottic closure (P = .003), and right mucosal wave (P = .016) improved after injection. CONCLUSIONS: Office-based steroid injection combined with voice therapy for mild/moderate vocal fold scar is associated with improved patient-reported and functional voice measures. These findings provide preliminary support for this approach. Importantly, the procedure is low risk and can be performed in the office, thus offering a simple treatment alternative to patients with a disorder that has traditionally been difficult to manage. Prospective studies evaluating the effects of multiple injections are warranted.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Young WG, Hoffman MR, Koszewski IJ, et al. Voice Outcomes following a Single Office-Based Steroid Injection for Vocal Fold Scar. Otolaryngol Head Neck Surg. 2016. PMID: 27507145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。